Efficacy of Memantine as an Adjuvant Therapy in Bipolar Disorder

Vice chancellor for research, Kurdistan University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•This study is performed on patients between the years2013 to2014 at Qods Hospital in Sanandaj admitted with a diagnosis of bipolar1 disorder in acute mania phase.
•history of bipolar disorder (manic acute phase), with or without psychotic symptoms according to DSM-IV-TR clinical interview by a psychiatrist; earn at least 20 points YMRS mania that has revealed; age 18 to 60 years old; obtaining informed consent from a parent or legal guardian of the patient; living in Sanandaj, Irann.
•Exclusion criteria: Alcohol and drug dependence or abuse during the 3 months prior to admission (excluding nicotine or caffeine); psychiatric disorders on Axis II (according to DSM-IV-TR), which can interfere with the study; delirium, dementia and cognitive disorders; Schizophrenia, schizoaffective disorder, and psychotic disorders; evidence of heart disease, kidney disease, liver disease (based on medical records) that may cause difficulty in the study; pregnancy and lactation; mental retardation based on clinical assessment, the therapist; history of drug allergy or adverse drug with risperidone and lithium carbonate or Memantine; any history of seizure; Memantine use of the 3 months prior to admission.

发起方

Vice chancellor for research, Kurdistan University of Medical Sciences